| Outcome Measures: |
Primary: Percentage change in LDL-C levels from baseline to Week 12, Week 12|Percentage of subjects with low-density lipoprotein cholesterol (LDL-C) levels of <100 mg/dL (LDL-C responders) at Week 12, Week 12 | Secondary: Percentage change from baseline in TC, high-density lipoprotein cholesterol, triglycerides, and high sensitivity C-reactive protein at Weeks 4, 8, and 12, Weeks 4, 8, and 12|Adverse events at Weeks 4, 8, and 12, Baseline and at Weeks 4, 8, and 12|Clinical laboratory changes at Weeks 4, 8, and 12, Screening and at Weeks 4, 8, and 12|Vital signs at Weeks 4, 8, and 12, Screening and at Weeks 4, 8, and 12|Percentage change in LDL-C levels from baseline at Weeks 4 and 8, Weeks 4 and 8|Percentage of LDL-C responders at Weeks 4 and 8, Weeks 4 and 8|Percentage of subjects with total cholesterol (TC) levels of <160 mg/dL (TC responders) at Weeks 4, 8, and 12, Weeks 4, 8, and 12
|
| Locations: |
Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Kaohsiung, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taoyuan Hsien, Taiwan
|
